📋 Tender Overview
The DAK-Gesundheit intends to conclude non-exclusive discount agreements for pharmaceuticals under the relevant legal provisions. This involves a formal procurement process for the active ingredient Dydrogesterone, ATC G03DB01, with interested pharmaceutical companies. The contracts will commence on October 1, 2026, and end on September 30, 2028, with an option for a 12-month extension. The procurement aims to ensure non-discriminatory access for all pharmaceutical companies. Dydrogesterone, ATC G03DB01
